CLINICAL TRIALS AND OBSERVATIONS Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
نویسندگان
چکیده
Ken H. Young,1-3 Karen Leroy,4 Michael B. Møller,5 Gisele W. B. Colleoni,6 Margarita Sánchez-Beato,7 Fábio R. Kerbauy,6 Corinne Haioun,4 Jens C. Eickhoff,1-3 Allen H. Young,1-3 Philippe Gaulard,4 Miguel A. Piris,7 Terry D. Oberley,1-3 William M. Rehrauer,1-3 Brad S. Kahl,1-3 James S. Malter,1-3 Elias Campo,8 Jan Delabie,9 Randy D. Gascoyne,10 Andreas Rosenwald,11 Lisa Rimsza,12 James Huang,13 Rita M. Braziel,13 Elaine S. Jaffe,14 Wyndham H. Wilson,14 Louis M. Staudt,14 Julie M. Vose,15 Wing C. Chan,15 Dennis D. Weisenburger,15 and Timothy C. Greiner15
منابع مشابه
The interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma Short title: IL-10 polymorphisms and lymphoma outcome
(4217 articles) Neoplasia (4939 articles) Immunobiology (3667 articles) Clinical Trials and Observations Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylib...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is characterized by a marked degree of morphologic and clinical heterogeneity. Establishment of parameters that can predict outcome could help to identify patients who may benefit from risk-adjusted therapies. BCL-6 is a proto-oncogene commonly implicated in DLBCL pathogenesis. A real-time reverse transcription–polymerase chain reaction assay was establishe...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In 3 sequential clinical trials, conducted from January 1993 to August 2000, we treated 150 patients with relapsed or pr...
متن کاملCLINICAL TRIALS AND OBSERVATIONS High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
The tumor microenvironment plays an important role in the biologic behavior of follicular lymphoma (FL), but the specific cell subsets involved in this regulation are unknown. To determine the impact of FOXP3-positive regulatory T cells (Tregs) in the progression and outcome of FL patients, we examined samples from 97 patients at diagnosis and 37 at first relapse with an anti-FOXP3 monoclonal a...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic markers. Since randomized controlled trials of R-CHOP in DLBCL have included select subgroups of pat...
متن کامل